Two upcoming webinars—one from Zebra Technologies focused on machine vision and another from the MRC Trials Center focused on clinical trials—signal where synthetic data is moving from concept to operational playbooks. For data, privacy, and compliance teams, the agenda is practical: scaling generation pipelines, validating realism, and reducing data-sharing risk.
Zebra and MRC schedule synthetic data webinars for manufacturing and trials
Zebra Technologies and the Medical Research Council (MRC) announced webinars covering synthetic data applications across manufacturing and clinical research. The sessions run on Nov. 18 and Nov. 20, 2025, with topics spanning machine vision, industrial automation, AI “digital twins,” and clinical trial design.
According to MVPro Media, the Zebra-focused session will examine synthetic data in machine vision and industrial automation, while the MRC Trials Center session will cover AI digital twins and the use of synthetic data in clinical trials, including control arm reduction and Bayesian trial design.
- For ML engineers: The manufacturing agenda (machine vision + automation) is a reminder that synthetic data programs live or die on reproducible pipelines—scene generation, labeling, domain randomization, and measurable lift against real-world test sets.
- For clinical data leads: Control-arm reduction and Bayesian designs put synthetic data directly in the critical path of trial methodology, increasing the need for clear assumptions, auditability, and pre-specified validation criteria.
- For privacy/compliance: These sessions are a low-cost way to benchmark “safer sharing” narratives against concrete practices—what is shared, under what controls, and how teams document risk and utility tradeoffs.